Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
First Affiliated Hospital of Zhejiang University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06850103CT.gov SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases | — | Recruiting | — | — | — |
NCT05877573CT.gov Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal Cancer | — | Recruiting | — | — | — |
NCT05815303CT.gov XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal Cancer | — | Unknown | — | — | — |
NCT05731726CT.gov Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | — | Recruiting | — | — | — |
NCT04659382CT.gov Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Marinesco-Sjogren Syndrome
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Capecitabine (this asset) | First Affiliated Hospital of Zhejiang University | P2 | CCC · 53 |
| Irinotecan | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Cetuximab | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Oxaliplatin | Sixth Affiliated Hospital, Sun Yat-sen University | P3 | B |
| Nivolumab | Pfizer | P2 | B |
| Ipilimumab | Pfizer | P2 | B |
| Binimetinib | Pfizer | P2 | B |
| Regorafenib | Sun Yat-sen University | P2 | CCC |
| rp3 | Replimune, Inc. | P2 | CCC |
+12 more in the Marinesco-Sjogren Syndrome cohort
Other indications for Capecitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Carcinoma | — | P4 | BBB · 73 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 72 |
| Colorectal Neoplasm | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Capecitabine in Marinesco-Sjogren Syndrome. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/capecitabine-marinesco-sjogren-syndrome
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →